Geron cuts out companion diagnostics
This article was originally published in Clinica
Geron has eliminated its companion diagnostic and drug discovery research programs, and reduced its work force by another 20 employees. Now the company's path forward depends solely on the results of an investigator-sponsored study for its lone drug candidate imetelstat in a single hematological indication.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.